- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | Lexaria Bioscience Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.07. | Lexaria Bioscience Corp.: Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study | 224 | ACCESSWIRE | DehydraTECH appears to work with a second GLP-1 drug - liraglutideDehydraTECH appears to be working with semaglutide both with and without SNAC technologyDehydraTECH-CBD is showing strong apparent performance... ► Artikel lesen | |
| 16.07. | Lexaria Bioscience Corp.: Lexaria Preparing For Strategic Growth | 165 | ACCESSWIRE | Strategic growth plan execution underway. KELOWNA, BC / ACCESSWIRE / July 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery... ► Artikel lesen | |
| 12.07. | Lexaria Bioscience Corp reports results for the quarter ended in May - Earnings Summary | 2 | Reuters | ||
| 12.07. | Lexaria Bioscience Corp. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.07. | Lexaria Bioscience Corp.: Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study | 386 | ACCESSWIRE | All three dosing arms have been completed. KELOWNA, BC / ACCESSWIRE / July 9, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery... ► Artikel lesen | |
| 08.07. | Lexaria Bioscience Corp.: Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy | 275 | ACCESSWIRE | Lexaria currently holding 46 granted patents worldwide KELOWNA, BC / ACCESSWIRE / July 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator... ► Artikel lesen | |
| 18.06. | Lexaria Bioscience Corp.: Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study | 354 | ACCESSWIRE | Weight Loss and Blood Sugar Reduction are Major Efficacy Objectives KELOWNA, BC / ACCESSWIRE / June 18, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX,)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global... ► Artikel lesen | |
| 05.06. | Lexaria Bioscience Corp.: Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study | 264 | ACCESSWIRE | Second study arm dosing is now complete. KELOWNA, BC / ACCESSWIRE / June 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery... ► Artikel lesen | |
| 03.06. | Lexaria Bioscience Corp. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 23.05. | Lexaria Bioscience Corp.: Lexaria Awards Contract For Third GLP-1 Human Pilot Study | 346 | ACCESSWIRE | First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral formatKELOWNA, BC / ACCESSWIRE / May 23, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the... ► Artikel lesen | |
| 21.05. | Lexaria Bioscience Corp.: Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy | 222 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / May 21, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces two important new... ► Artikel lesen | |
| 17.05. | Lexaria Bioscience Corp.: Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study | 497 | ACCESSWIRE | Study WEIGHT-A24-1 will evaluate DehydraTECH-processed pure semaglutide and liraglutideWill DehydraTECH processing result in higher brain absorption of GLP-1 drugs? KELOWNA, BC / ACCESSWIRE / May 17... ► Artikel lesen | |
| 08.05. | Lexaria Bioscience Corp.: Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study | 241 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / May 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study... ► Artikel lesen | |
| 06.05. | Lexaria Bioscience Corp.: Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs | 1.052 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / May 6, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces an applied research... ► Artikel lesen | |
| 30.04. | Lexaria Bioscience Corp.: Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance | 345 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / April 30, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has entered... ► Artikel lesen | |
| 24.04. | Lexaria Bioscience Corp. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | Lexaria Bioscience, Biosig Technologies, BIMI Holdings among healthcare movers | 1 | Seeking Alpha | ||
| 16.04. | Lexaria gets ethics board okay for oral GLP-1 study | 1 | Seeking Alpha | ||
| 16.04. | Lexaria Bioscience Corp.: Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study | 546 | ACCESSWIRE | Human Pilot Study #2 (GLP-1-H24-2) Approved KELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug... ► Artikel lesen |
Seite:
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EMEIS | 13,230 | +1,21 % | emeis: Growth in Revenue in First-Half 2024 at €2,772 Million (Up 9.2%) | Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240726471228/en/
emeis (Paris:EMEIS):
Growth in revenue in first-half... ► Artikel lesen | |
| NANO-X IMAGING | 8,590 | +9,29 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| GLOBAL HEMP GROUP | 0,022 | 0,00 % | XFRA GHG0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| BUTTERFLY NETWORK | 1,065 | -2,29 % | Butterfly Network Reports First Quarter 2024 Financial Results | BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with handheld, whole-body ultrasound... ► Artikel lesen | |
| GOODRX | 8,850 | +1,26 % | Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira | First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx (Nasdaq: GDRX),... ► Artikel lesen | |
| CARMAT | 2,600 | +0,58 % | CARMAT accelerates its sales momentum and reiterates its confidence in its development outlook | 20 implants of the Aeson artificial heart performed in the first half of 2024
Pace of 4 implants per month in the second quarter
Half-year sales at €3.2 million, higher than the... ► Artikel lesen | |
| JOINT CORP | 14,220 | +4,33 % | The Joint Corp. to Host Conference Call on Thursday, August 8th to Discuss Second Quarter 2024 Results | ||
| HYPERFINE | 1,170 | +1,74 % | Hyperfine, Inc. - 8-K, Current Report | ||
| MIMEDX | 7,760 | +0,65 % | MiMedx Group, Inc: MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature - Scientific Reports | ||
| PROGYNY | 29,140 | +1,89 % | Progyny, Inc. Announces Details for Its Second Quarter 2024 Results Report | ||
| OUTSET MEDICAL | 3,740 | +0,81 % | Outset Medical Reports First Quarter 2024 Financial Results | SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 61,85 | -3,96 % | Procept Biorobotics: Point72 Europe London LLP hat 123800 Aktien dazugekauft! | Medizintechnik-Unternehmen mit 58%-Halbjahresrallye bei Procept Biorobotics (PRCT) Immer noch rote Zahlen, aber viel Potenzial! Procept Biorobotics (PRCT) - ISIN US74276L1052 Rückblick: Das Medizintechnik-Unternehmen... ► Artikel lesen | |
| BIOMERICA | 0,351 | +0,40 % | Biomerica, Inc.: Biomerica Announces inFoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024 | With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th... ► Artikel lesen | |
| ATRION | 420,00 | 0,00 % | Dividendenbekanntmachungen (14.06.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AARONS COMPANY INC US00258W1080 0,125 USD 0,1163 EUR ADAMS RESOURCES & ENERGY INC US0063513081 0,24 USD 0,2234 EUR AEGON LTD BMG0112X1056 - 0... ► Artikel lesen | |
| ATRICURE | 22,120 | -5,99 % | AtriCure (ATRC) Gains China Approval for AtriClip LAA System |
LEXARIA BIOSCIENCE CORP gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 3,380 Euro und damit +9,39 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXARIA BIOSCIENCE CORP finden Sie auf Wallstreet Online.
